Cargando…

Recent advances in understanding idiopathic pulmonary fibrosis

Despite major research efforts leading to the recent approval of pirfenidone and nintedanib, the dismal prognosis of idiopathic pulmonary fibrosis (IPF) remains unchanged. The elaboration of international diagnostic criteria and disease stratification models based on clinical, physiological, radiolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daccord, Cécile, Maher, Toby M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000Research 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890320/ https://www.ncbi.nlm.nih.gov/pubmed/27303645 http://dx.doi.org/10.12688/f1000research.8209.1

Ejemplares similares

Evaluating disease severity in idiopathic pulmonary fibrosis
por: Robbie, Hasti, et al.
Publicado: (2017)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Recent Advances in Idiopathic Pulmonary Fibrosis
por: Park, Sanghoon, et al.
Publicado: (2013)

Recent advances in managing idiopathic pulmonary fibrosis
por: Scelfo, Chiara, et al.
Publicado: (2017)

Current and novel drug therapies for idiopathic pulmonary fibrosis
por: Adamali, Huzaifa I, et al.
Publicado: (2012)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
por: Maher, Toby M.
Publicado: (2021)

Recent advances in the genetics of idiopathic pulmonary fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2023)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations
por: Skolnik, Kate, et al.
Publicado: (2018)

Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?
por: Maher, Toby M.
Publicado: (2021)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
por: Strongman, Helen, et al.
Publicado: (2018)

The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

The Role of the Lung’s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2019)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?
por: Maher, Toby M.
Publicado: (2022)

Advances in the management of idiopathic pulmonary fibrosis
por: Ryu, Jay H, et al.
Publicado: (2010)

Global incidence and prevalence of idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Precision medicine advances in idiopathic pulmonary fibrosis
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies
por: Guo, Hehua, et al.
Publicado: (2023)

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

Pathogenesis of idiopathic pulmonary fibrosis: review of recent findings
por: Renzoni, Elisabetta, et al.
Publicado: (2014)

Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions
por: Ruigrok, Mitchel J.R., et al.
Publicado: (2021)

Azithromycin alters spatial and temporal dynamics of airway microbiota in idiopathic pulmonary fibrosis
por: Gijs, Pieter-Jan, et al.
Publicado: (2023)

Recent advances in understanding bile duct remodeling and fibrosis
por: Scrushy, Marinda, et al.
Publicado: (2018)

Advances in cellular senescence in idiopathic pulmonary fibrosis (Review)
por: Han, Shan, et al.
Publicado: (2023)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Idiopathic pulmonary fibrosis
por: Meltzer, Eric B, et al.
Publicado: (2008)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis
por: Yung, Susan, et al.
Publicado: (2017)

Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis
por: Stewart, Iain D., et al.
Publicado: (2021)

Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study
por: Nolan, Claire M, et al.
Publicado: (2021)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Cough in idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2016)

Epidemiology of idiopathic pulmonary fibrosis
por: Ley, Brett, et al.
Publicado: (2013)

Idiopathic Pulmonary Fibrosis and Telomeres
por: Mulet, Alba, et al.
Publicado: (2022)

Management of Idiopathic Pulmonary Fibrosis
por: Pleasants, Roy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kto518hes1pib5qhfun55ed4bg